



ASX Announcement

26 February 2019

Collaboration Agreement with Summit Biomedical Imaging LLC (SBI)

Optiscan is pleased to announce that it has entered into a collaboration agreement with SBI for the purposes of discussions regarding commercialization of a drug/device combination for various clinical applications involving SBI's PARPi-FL imaging agent and Optiscan's FIVE2 (Viewnvivo) confocal endomicroscope. These applications include using PARPi-FL in the breast cancer tumour margin assessment trial currently being conducted by Optiscan.

About Summit Biomedical Imaging

SBI is a biomedical technology company focused on developing innovative biomedical technologies for cancer diagnosis and treatment. SBI has been awarded a federal grant (U.S.) through NIH's Small Business Innovation Research (SBIR) program to support investigation of a diagnostic imaging agent (PARPi-FL) which targets PARP1, an enzyme that is highly overexpressed in several human cancers, including oral squamous cell carcinoma and cervical cancer.

About Optiscan

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes, and is a global leader in the development and application of microscopic imaging and related technologies for medical and research markets.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

Phone (61 3) 9538 3333

Website www.optiscan.com

PO Box 1066, Mt Waverley MDC VIC 3149 Australia